/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lixte Biotechnology Holdings Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.193 0.0345(3.45%) LIXT at 04 Dec 2025 04:37 PM Biotechnology
Lowest Today 4.02
Highest Today 4.2299
Today’s Open 4.02
Prev. Close 4.06
52 Week High 6.26
52 Week Low 0.64
Day’s Range: Low 4.02 High 4.2299
52-Week Range: Low 0.64 High 6.26
1 day return -
1 Week return -4.35
1 month return +1.21
3 month return -7.53
6 month return +206.61
1 year return +110.6
3 year return -39.56
5 year return -88.76
10 year return -

Institutional Holdings

HighTower Advisors, LLC 2.18

Ethos Financial Group LLC 0.54

Geode Capital Management, LLC 0.45

Fidelity Extended Market Index 0.37

Atlas Legacy Advisors, LLC 0.30

Vanguard Institutional Extnd Mkt Idx Tr 0.12

Tower Research Capital LLC 0.07

Fidelity Series Total Market Index 0.06

Spartan Total Market Index Pool G 0.03

UBS Group AG 0.02

Fidelity Nasdaq Composite Index 0.02

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

SBI Securities Co Ltd 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Bank of America Corp 0.00

Spartan Extended Market Index Pool F 0.00

CLEAR STREET LLC. 0.00

SSgA U.S. Total Market Index Strategy 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Citadel Advisors Llc 0.00

FNY Investment Advisers, LLC 0.00

TIAA Trust National Association 0.00

Market Status

Fundamentals

Market Cap 25.46 M

PB Ratio 11.3507

PE Ratio 0.0

Enterprise Value 23.99 M

Total Assets 1.15 M

Volume 77892

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-5686078 -5.7M, FY22:-6304714 -6.3M, FY21:-6735184 -6.7M, FY20:-3263324 -3.3M, FY19:-2390620 -2.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-2030765 -2.0M, Q2/2025:-775673 -0.8M, Q1/2025:-709555 -0.7M, Q3/2024:-986030 -1.0M, Q2/2024:-1010919 -1.0M

Fund house & investment objective

Company Information Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Organisation Biotechnology

Employees 2

Industry Biotechnology

CEO Mr. Geordan G. Pursglove

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow